Data Insights

Ipilimumab by Bristol-Myers Squibb for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

Ipilimumab by Bristol-Myers Squibb for Metastatic Uveal Melanoma: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Metastatic Uveal Melanoma

Data Insights

Ipilimumab by Bristol-Myers Squibb for Uveal Melanoma: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Uveal Melanoma

Data Insights

Ipilimumab by Bristol-Myers Squibb for Myeloproliferative Disorders: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Myeloproliferative Disorders. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Myeloproliferative Disorders

Data Insights

Ipilimumab by Bristol-Myers Squibb for Myelodysplastic Syndrome: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Myelodysplastic Syndrome

Data Insights

Ipilimumab by Bristol-Myers Squibb for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

Ipilimumab by Bristol-Myers Squibb for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Chronic Myelocytic Leukemia (CML, Chronic Myeloid...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Data Insights

Ipilimumab by Bristol-Myers Squibb for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Ipilimumab by Bristol-Myers Squibb for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Ipilimumab by Bristol-Myers Squibb for Non-Hodgkin Lymphoma: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Non-Hodgkin Lymphoma

Data Insights

Ipilimumab by Bristol-Myers Squibb for Ovarian Cancer: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Ovarian Cancer

Data Insights

Ipilimumab by Bristol-Myers Squibb for Neuroendocrine Tumors: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Neuroendocrine Tumors

Data Insights

Ipilimumab by Bristol-Myers Squibb for Vaginal Cancer: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Vaginal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Vaginal Cancer

Data Insights

Ipilimumab by Bristol-Myers Squibb for Uterine Cancer: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Uterine Cancer

Data Insights

Ipilimumab by Bristol-Myers Squibb for Gallbladder Cancer: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Gallbladder Cancer

Data Insights

Ipilimumab by Bristol-Myers Squibb for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Ipilimumab by Bristol-Myers Squibb for Soft Tissue Sarcoma: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Soft Tissue Sarcoma

Data Insights

Ipilimumab by Bristol-Myers Squibb for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Ipilimumab by Bristol-Myers Squibb for Multiple Myeloma (Kahler Disease): Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Multiple Myeloma (Kahler Disease). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Multiple Myeloma (Kahler Disease)

Data Insights

Ipilimumab by Bristol-Myers Squibb for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According...

Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Metastatic Adenocarcinoma of The Pancreas